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Purpose: Examine illness perceptions, functional health and quality of life of lung cancer
patients throughout chemotherapy treatment.
Patients and Methods: Longitudinal design with baseline measure 12 days after the ﬁrst
chemotherapy and follow-up measure 3 months later, where illness perceptions (BIPQ),
functional health, and quality of life (EORTC QLQ-C-30) were measured. A total of 21
patients with non-small-cell lung cancer took part. Non-parametric testing was performed
given the pilot nature of the study and the associated relatively small sample size.
Results: Small to medium changes in illness perceptions and functional health between the
two measurement points were detected, with both becoming more positive. More negative
illness perceptions at the beginning of the treatment were associated with less functioning
and lower quality of life at both beginning and end of treatment.
Conclusion: Addressing illness perceptions seems a clinically relevant approach in improv-
ing functioning and quality of life of patients with non-small-cell lung cancer.
Keywords: lung cancer, illness perceptions, quality of life, longitudinal design, patient
reported outcomes
Introduction
In the past decade, a number of advances in the medical treatment and diagnosis of
lung cancer have notably increased survival rates.1 Due to this development, the
investigation of psychological outcomes as assessed via patient reported outcome
measures in lung cancer patients becomes more and more relevant.2,3 Quite a few
studies even showed that QOL is a positive predictor of survival in lung cancer
patients.4–8 Therefore, understanding determinants of the psychological outcomes
such as QOL is crucial in order to maximize QOL and consequently survival.
One of the most promising psychological concepts that is related to various
illness outcomes in chronic patients appears to be illness perceptions (IPs). IPs are
the cognitive and emotional responses of patients to their illness and its medical
management.9 IPs do not necessarily reﬂect “medically correct facts” and differ
quite substantially from accepted medical wisdom. In line with the assumptions of
the common-sense model of self-regulation of health and illness,9 various empirical
studies showed that IPs have an impact on illness outcomes, such as functional
health and QOL, directly and indirectly via illness behavior.10–12 Therefore, addres-
sing IPs and attempting to change them can contribute to the overall well-being of
patients.
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The aim of the current paper is to investigate the course
of IPs and psychological outcomes, ie, functional health and
QOL, in lung cancer patients over a 3-month period during
chemotherapy. Moreover, the relationships between illness
perceptions and psychological outcomes is examined.
Methods
The presented data are part of a larger international, bicen-
ter study on illness perceptions and QOL in cancer
patients.13 The study was conducted in line with the
Helsinki Declaration. The study protocol was approved
by the Medical Ethics Committee of the Leiden
University Medical Center, the Netherlands (#P12-090)
and written informed consent was obtained from all
participants.
Procedure
Patients were recruited in the Leiden University Medical
Center, the Netherlands. Patients were included if they had
the diagnosis of non-small-cell lung carcinoma (NSCLC)
of any stage and were undergoing ﬁrst-line adjuvant or
neo-adjuvant chemotherapy. Patients with EGFR or ALK
mutations and patients undergoing concurrent radiotherapy
and chemotherapy were excluded, in order to obtain
a homogenous sample regarding clinical characteristics
and type of therapy.
Data were collected at two-time points, ie, at the begin-
ning of the treatment, approximately 12 days after the ﬁrst
round of chemotherapy and 1 month after the last round of
chemotherapy, approximately 3 months later.
Measures
The Dutch version of Brief Illness Perception
Questionnaire (Brief IPQ)14 was used to measure ﬁve
cognitive illness perceptions (ie, consequences, timeline,
personal control, treatment control, identity), two emo-
tional illness perceptions (ie, concern, emotions) and ill-
ness comprehensibility with one item each (range 0–10).
Higher scores indicate stronger perceptions that lung can-
cer affects the life, has a long duration, can be controlled
by own behavior or medical treatment, involves much
complaints, elicits concerns, produces negative emotions,
and is understandable.
The Dutch version of the EORTC Quality of Life
Questionnaire version 3.0 (EORTC QLQ-C30)15 was
used to assess functional health and global QOL.
Functional health was measured with 15 items that were
combined into ﬁve subscales, ie, physical, role, emotional,
cognitive, and social functioning. Global QOL was mea-
sured with two items. All subscales were linearly trans-
formed (range 0 to 100), with higher scores indicating
better functional health and higher QOL.
Participants
Thirty patients were included and completed the baseline
measurement. Of these, nine patients did not return the
follow-up questionnaires, which resulted in a ﬁnal sample
of 21 patients (female: n=13, 61.9%). The sample included 1
patient (4.8%) with stage IIA, 2 patients (9.5%) with stage
IIB, 5 patients (23.8%) with stage IIIA, and 13 patients
(61.9%) with stage IV non-small-cell lung carcinoma. Most
patients (n=17, 81.0%) had no comorbidity. The mean age of
the patients was 64.62 years (SD=7.70; range 53–82 years).
Data Analyses
Due to the small sample size, the data were analyzed by
using nonparametric statistical tests. To explore the course
of IPs, functional health, and QOL throughout chemother-
apy, Wilcoxon signed-rank tests comparing scores at base-
line with scores at follow-up were computed. The
relationships between IPs at baseline and functional health
and QOL at baseline and at follow-up were examined by
means of Kendall’s tau-b correlations. Due to the small
sample size and consequently suboptimal power, signiﬁ-
cance from p<0.10 is reported and the effect size was
taken into account when interpreting the results.
Results
IPs, Functional Health, and QOL at
Baseline and Follow-Up
Table 1 (upper part) shows some small changes in IPs
between baseline and follow-up. After the chemotherapy,
patients reported less perceived consequences, less personal
control, less experienced symptoms, and less concern com-
pared to the beginning of the chemotherapy. These changes
seem to be discernible also on a few dimensions of func-
tional health. Emotional and cognitive functioning improved
moderately and slightly, respectively (lower part Table 1).
Relationships Between IPs and Functional
Health and QOL
Table 2 shows a large number of meaningful relationships of
IPs at baseline with functional health and global QOL at
baseline and follow-up. The IPs consequences, timeline, per-
sonal control, identity, concern, and understanding showed the
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most and the strongest correlations with various dimensions
of functional health and QOL at both measurement points.
Discussion
IPs and psychological outcomes of our patients at the
beginning of the chemotherapy are comparable to earlier
ﬁndings in lung cancer patients.13 Previous research
showed that chemotherapy negatively affects the general-
ized health-related quality of life.16 We expand this ﬁnding
by showing that IPs become slightly more positive and
aspects of functional health slightly increase after che-
motherapy. Interestingly, in the present study, QOL
seems not to improve after chemotherapy.
At the beginning of chemotherapy, IPs were signiﬁ-
cantly associated with various aspects of functional
health and QOL. More importantly, IPs at the beginning
of chemotherapy were also prospectively related to these
outcome measures after chemotherapy. Speciﬁcally, the
perception of more serious consequences, a longer time-
line, more personal control, more negative emotions,
and a better understanding of lung cancer predict
lower functional health and QOL. These ﬁndings are
largely in line with previous research in cancer
patients,17 except from the remarkable ﬁnding that
a better understanding of lung cancer has a negative
effect on the outcome measures.
Table 1 Comparisons of Illness Perceptions, Functional Health, and Quality of Life at Baseline and Follow-Up (Wilcoxon Signed-Rank Test)
Na M (SD) Md Baseline M (SD) Md Follow-Up Z (rb)
Illness Perceptions
Consequences 20 6.60 (2.95) 8.00 5.65 (2.81) 6.00 −1.13 (0.25)
Timeline 19 6.37 (2.61) 5.00 6.79 (3.01) 7.00 −0.52 (0.12)
Personal control 20 4.68 (3.01) 5.00 4.00 (2.90) 4.00 −1.31 (0.29)
Treatment control 20 7.70 (1.75) 8.00 7.65 (2.03) 8.00 −0.20 (0.04)
Identity 20 5.20 (2.61) 5.00 3.75 (2.69) 5.00 −1.68(*) (0.38)
Concern 19 6.26 (2.77) 7.00 5.32 (2.91) 5.50 −1.19 (0.27)
Understanding 19 7.53 (2.34) 8.00 7.21 (2.02) 7.50 −0.55 (0.13)
Emotions 20 4.80 (3.05) 4.00 4.45 (2.78) 4.0 −0.61 (0.14)
Functional Health and Quality of Life
Physical functioning 21 74.29 (19.47) 80.00 71.19 (18.19) 73.34 −0.97 (0.21)
Role functioning 21 60.32 (26.07) 66.67 53.17 (31.89) 50.00 −0.84 (0.18)
Emotional functioning 21 73.02 (24.57) 83.34 81.35 (22.96) 83.34 −1.99* (0.43)
Cognitive functioning 21 78.57 (24.80) 83.34 83.33 (16.67) 83.34 −0.98 (0.21)
Social functioning 21 73.81 (21.46) 83.34 71.43 (26.43) 83.34 −0.18 (0.04)
Global QOL 21 59.52 (23.76) 66.67 63.10 (18.55) 66.67 −0.24 (0.05)
Notes: aN varies due to missing data. bEffect size r = Z/√N. r≥0.1 = small effect, r≥0.3 = medium effect, r≥0.5 = large effect. *p<0.05, (*)p<0.10.
Table 2 Kendall’s Tau-b Correlations Between Illness Perceptions at Baseline and Functional Health and Quality of Life at Baseline and
Follow-Up
Physical
Functioning
Baseline/Follow-
Up
Role
Functioning
Baseline/Follow-
Up
Emotional
Functioning
Baseline/
Follow-Up
Cognitive
Functioning
Baseline/
Follow-Up
Social
Functioning
Baseline/
Follow-Up
Global QOL
Baseline/Follow-
Up
Consequences −0.56** −0.31(*) −0.39* −0.37* −0.35(*) −0.01 −0.42* −0.31 −0.39* −0.41* −0.25 −0.15
Timeline −0.31(*) −0.39* −0.13 −0.32(*) −0.08 0.05 −0.31(*) −0.17 −0.08 −0.42* −0.03 −0.07
Personal control −0.08 −0.01 −0.30(*) −0.22 −0.22 −0.27 −0.27 −0.12 −0.21 −0.40* −0.26 −0.10
Treatment control 0.34(*) −0.08 0.33(*) −0.02 0.18 −0.02 0.38* 0.30 0.01 −0.15 0.41* −0.16
Identity −0.62*** −0.18 −0.58** −0.04 −0.31(*) −0.08 −0.36(*) −0.08 −0.18 −0.09 −0.69*** −0.07
Concern −0.42* −0.08 −0.29 −0.15 −0.41* −0.14 −0.36(*) −0.11 −0.15 −0.19 −0.52** −0.05
Understanding −0.01 −0.38* −0.04 −0.40* −0.09 −0.16 −0.13 0.07 0.10 −0.39* −0.15 −0.34(*)
Emotions −0.19 −0.01 −0.49** −0.20 −0.15 −0.10 −0.24 0.01 −0.12 −0.18 −0.44* −0.35*
Notes: N ranges between 19 and 20 due to missing data. τb≥0.1 = small effect, τb≥0.3 = medium effect, τb≥0.5 = large effect. ***p<0.001, **p<0.01, *p<0.05,
(*)p<0.10.
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Conclusion and Future Directions
The number of respondents in our study must be deemed to
be rather small. Patients in whom NSCLC has been diag-
nosed become quite ill quite soon, and they ﬁnd it burden-
some to ﬁll out questionnaires, limiting empirical studies on
quality of life (in a broad sense) in these patients.18–20
Despite this limitation, our ﬁndings suggest that IPs of
lung cancer patients play an important role in functional
health and QOL, and should therefore be taken into con-
sideration during medical treatment. Communicating about
emotions and concerns seems to be most critical.21 Purely
providing patients with clinical information in order to
satisfy their information needs22 without discussing psycho-
social issues23 might be detrimental as our ﬁndings indicate
that a better understanding of lung cancer worsens function-
ing and QOL in the long run. Teaching physicians to
address, discuss and help adjust unhelpful illness percep-
tions in patients with NSCLC leads to less adjustment pro-
blems in the patients and their caregivers.24,25 Future studies
with larger sample sizes should investigate whether addres-
sing IPs in lung cancer patients impact on patient related
outcome measures.
Abbreviations
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